Draft monograph: retatrutide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The analytical section assumes a reference standard that is not generally available — arising from DRAFT-RETATRUTIDE-/001. The analytical section now states whether a reference standard is in general circulation for this compound and, where it is not, states which determinations remain possible and which become qualitative. A content figure obtained without a reference standard…
2. The interaction section lists mechanisms rather than interactions — arising from DRAFT-RETATRUTIDE-/002. The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.
3. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-RETATRUTIDE-/003. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
4. The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-RETATRUTIDE-/004. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.
5. What happens when the compound is stopped is not addressed — arising from DRAFT-RETATRUTIDE-/005. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
6. Nothing is said about impaired renal or hepatic clearance — arising from DRAFT-RETATRUTIDE-/006. The pharmacokinetic table now carries renal and hepatic rows in every monograph, populated with the study where one exists and with an explicit statement of absence where none does.
7. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-RETATRUTIDE-/007. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
8. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-RETATRUTIDE-/008. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
9. A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-RETATRUTIDE-/009. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
10. The indication table mixes approved indications with uses for which the compound is merely supplied — arising from DRAFT-RETATRUTIDE-/010. The indication table now carries a status column with three values, approved, under investigation and supplied without trial evidence, and the value is stated for every row. Rows in the third category also state that no certainty rating is assigned because…
11. The mechanism section is written with more confidence than the clinical section it precedes — arising from DRAFT-RETATRUTIDE-/012. Every pharmacology section now closes with a statement identifying which described actions are supported by clinical evidence assessed in §3 and which are not. The pharmacology itself is stated as the sources state it.
12. The same concept is given three different names in one document — arising from DRAFT-RETATRUTIDE-/013. A single term is now used throughout for each defined concept, and the glossary entry is linked at first use within each section rather than once per document.
13. Glycaemic trials and weight-management trials are drawn on interchangeably — arising from DRAFT-RETATRUTIDE-/014. Every effect estimate now names its programme, and the assessed-outcome table is split where a compound has more than one.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.